The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma
Abstract
Context: Because very few studies have examined the correlation between BRAF mutations and clinicopathological features of papillary thyroid carcinoma (PTC), we analyzed here a large and homogeneous cohort of patients with PTC for the presence of the BRAF mutation. Objective: We examined BRAF mutations in a consecutive series of 500 PTC patients who underwent surgery in the Department of Surgery of the University of Pisa, and we correlated the presence of the mutation with clinicopathological parameters of the patients: age, gender, tumor size, presence of tumor capsule, extrathyroidal invasion, multicentricity, presence of node metastases, and tumor class. Design: BRAF (exon 15) mutation was examined by PCR-single strand conformational polymorphism followed by DNA sequencing in laser-capture microdissected tissue samples. Results: In this study, BRAF mutation was found in 219 of 500 cases (43.8%). In particular, we found the most common BRAF V600E mutation in 214 cases (42.8%), BRAF K601E mutation in three cases (0.6%), BRAF VK600–1E (0.2%) in one case, whereas in one case we found a new 14-bp deletion with concomitant 2-bp insertion, VKSR600–3del and T599I, respectively. BRAF V600E was associated with extrathyroidal invasion (P < 0.0001), multicentricity (P = 0.0026), presence of nodal metastases (P = 0.0009), class III vs. classes I and II (P < 0.00000006), and absence of tumor capsule (P < 0.0001), in particular in follicular- and micro-PTC variants. By multivariate analysis, the absence of tumor capsule remained the only parameter associated (P = 0.0005) with BRAF V600E mutation. Conclusions: Our data suggest that BRAF V600E mutation is associated with high-risk PTC and in particular in follicular variant with invasive tumor growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer
Mazzaferri, E. L., & Jhiang, S. M. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90321-2 · Cited by 2,635
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,003
Durante, C., Haddy, N., Baudin, E., Leboulleux, S., Hartl, D., Travagli, J. P., Caillou, B., Ricard, M., Lumbroso, J. D., De Vathaire, F., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2838 · Cited by 1,675
Papillary and Follicular Thyroid Carcinoma
Schlumberger, M. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380506 · Cited by 1,623
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
Nikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030838 · Cited by 1,042
Self-citationBRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0987 · Cited by 993
Pathogenetic mechanisms in thyroid follicular-cell neoplasia
Kondo, T., Ezzat, S., & Asa, S. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1836 · Cited by 893
Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers
Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T. I., Ohtsuru, A., Saenko, V. A., Kanematsu, T., & Yamashita, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030305 · Cited by 533
Follicular variant of papillary thyroid carcinoma: A clinicopathologic study of a problematic entity
Liu, J., Singh, B., Tallini, G., Carlson, D. L., Katabi, N., Shaha, A., Tuttle, R. M., & Ghossein, R. A. (2006) · Cancer · doi:10.1002/cncr.22138 · Cited by 416
National Thyroid Cancer Treatment Cooperative Study Registr Group, Sherman, S. I., Brierley, J. D., Sperling, M., Ain, K. B., Bigos, S. T., Cooper, D. S., Haugen, B. R., Ho, M., Klein, I., et al. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980901)83:5<1012::aid-cncr28>3.0.co;2-9 · Cited by 402
Lee, J., Lee, E., & Kim, Y. (2007) · Cancer · doi:10.1002/cncr.22754 · Cited by 291
BRAFV599EMutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas
Puxeddu, E., Moretti, S., Elisei, R., Romei, C., Pascucci, R., Martinelli, M., Marino, C., Avenia, N., Rossi, E. D., Fadda, G., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031425 · Cited by 260
Self-citationSalvatore, G., Giannini, R., Faviana, P., Caleo, A., Migliaccio, I., Fagin, J. A., Nikiforov, Y. E., Troncone, G., Palombini, L., Basolo, F., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032221 · Cited by 259
Self-citationTrovisco, V., Soares, P., Preto, A., de Castro, I. V., Lima, J., Castro, P., Máximo, V., Botelho, T., Moreira, S., Meireles, A. M., et al. (2005) · Virchows Archiv · doi:10.1007/s00428-005-1236-0 · Cited by 253
RET/PTC Rearrangements and BRAF Mutations in Thyroid Tumorigenesis
Ciampi, R., & Nikiforov, Y. E. (2007) · Endocrinology · doi:10.1210/en.2006-0921 · Cited by 241
Fugazzola, L., Puxeddu, E., Avenia, N., Romei, C., Cirello, V, Cavaliere, A., Faviana, P., Mannavola, D., Moretti, S., Rossi, S., et al. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01086 · Cited by 237
Self-citationFahey, T. J. (2006) · Yearbook of Surgery · doi:10.1016/s0090-3671(08)70420-8 · Cited by 218
Long-Term Outcome of Patients With Differentiated Thyroid Carcinoma: Effect of Therapy
Mazzaferri, E. L. (2000) · Endocrine Practice · doi:10.4158/ep.6.6.469 · Cited by 200
BRAF mutations in an Italian cohort of thyroid cancers
Fugazzola, L., Mannavola, D., Cirello, V., Vannucchi, G., Muzza, M., Vicentini, L., & Beck‐Peccoz, P. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02089.x · Cited by 184
Encapsulated Follicular Variant of Papillary Thyroid Carcinoma with Bone Metastases
Baloch, Z. W., & LiVolsi, V. A. (2000) · Modern Pathology · doi:10.1038/modpathol.3880153 · Cited by 175
Mesa, C. O., Mirza, M., Mitsutake, N., Sartor, M. A., Medvedovic, M., Tomlinson, C. R., Knauf, J. A., Weber, G. F., & Fagin, J. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0739 · Cited by 136
Soares, P., Trovisco, V., Rocha, A. S., Feij�o, T., Rebocho, A. P., Fonseca, E., de Castro, I. V., Cameselle‐Teijeiro, J., Cardoso-Oliveira, M., & Sobrinho-Sim�es, M. (2004) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-004-1018-0 · Cited by 124
A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma
Trovisco, V., Soares, P., Soares, R., Magalhães, J., Sá-Couto, P., & Sobrinho-Simões, M. A. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.04.011 · Cited by 100
B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas
Trovisco, V., Soares, P., & Sobrinho-Simões, M. A. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.03.013 · Cited by 81
The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma
Sedliarou, I., Saenko, V., Lantsov, D., Rogounovitch, T., Namba, H., Abrosimov, A., Lushnikov, E. F., Kumagai, A., Nakashima, M., Meirmanov, S. K., et al. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.6.1729 · Cited by 80
Molecular pathology of well-differentiated thyroid carcinomas
Sobrinho-Simões, M. A., Preto, A., Rocha, A. S., Castro, P., Máximo, V., Fonseca, E., & Soares, P. (2005) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-005-0065-5 · Cited by 78
Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis
Kim, K., Suh, K., Kang, D., & Kang, D. (2005) · Pathology International · doi:10.1111/j.1440-1827.2005.01866.x · Cited by 71
Pathologic diagnosis of papillary thyroid carcinoma: today and tomorrow
Baloch, Z. W., & LiVolsi, V. A. (2005) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.5.4.573 · Cited by 45
Cited by
Nikiforov, Y. E., Seethala, R. R., Tallini, G., Baloch, Z. W., Basolo, F., Thompson, L. D. R., Barletta, J. A., Wenig, B. M., Al Ghuzlan, A., Kakudo, K., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0386 · Cited by 1,404
Self-citationMolecular genetics and diagnosis of thyroid cancer
Nikiforov, Y. E., & Nikiforova, M. N. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.142 · Cited by 1,011
Xing, M. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0007 · Cited by 983
Thyroid Cancer Epidemiology and Prognostic Variables
Sipos, J. A., & Mazzaferri, E. L. (2010) · Clinical Oncology · doi:10.1016/j.clon.2010.05.004 · Cited by 514
Thyroid Cancer Gender Disparity
Rahbari, R., Zhang, L., & Kebebew, E. (2010) · Future Oncology · doi:10.2217/fon.10.127 · Cited by 511
Metadata
- Authors
- Lupi, C., Giannini, R., Ugolini, C., Proietti, A., Berti, P., Minuto, M., Materazzi, G., Elisei, R., Santoro, M., Miccoli, P., & Basolo, F.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-11-01
- Volume
- 92
- Issue
- 11
- Pages
- 4085-4090
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2011699883
- Cited by
- 391
- References
- 30
- FWCI
- 15.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.